Processa Pharmaceuticals, Inc. — Director's Dealing 2024

Jan 31, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2024-01-30

Reporting Person: Yorke Justin W (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-30	Common Stock	P	8000	$2.693	Acquired	31232	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3737	Direct

Footnotes

F1: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.